Abcam, ab247277, Anti-General Receptor for phosphoinositides 1/GRASP antibody [EP394Y] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal General Receptor for phosphoinositides 1/GRASP antibody. Carrier free. Suitable for WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EP394Y,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab247277 is the carrier-free version of
ab33886
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The General Receptor for Phosphoinositides 1 (GRASP) also known as GRP1 is a protein that functions as a phosphoinositide-binding protein and regulates cellular membrane dynamics. It has a mass of approximately 97 kDa. GRASP is expressed in various tissues with significant presence in the brain and immune cells. Mechanically GRASP interacts with phosphoinositides on cellular membranes which assists in membrane trafficking and signaling.
Biological function summary
GRASP has a role in modulating intracellular transport processes and is critical in endosomal trafficking. It operates as part of a larger complex that regulates the recycling of membranes and proteins within cells. GRASP aids in ensuring that the proteins and membranes reach their intended cellular destinations maintaining cellular homeostasis.
Pathways
The protein is an important participant in the phosphoinositide 3-kinase (PI3K) signaling pathway an important pathway in cell growth proliferation and survival. GRASP interacts with proteins such as ARF6 influencing membrane dynamics and cellular signaling. Involved in these pathways GRASP contributes to proper cellular responses to extracellular signals and impacts various downstream biological effects.
GRASP plays a critical role in neurological disorders and immune system irregularities. Disruptions in GRASP function can be associated with conditions like Parkinson's disease and systemic lupus erythematosus (SLE). In Parkinson's GRASP interacts with proteins like LRRK2 suggesting a link between phosphoinositide signaling and neurodegenerative pathogenesis. In the immune context alterations in GRASP function seem connected to immune cell signaling irregularities influencing SLE development.